Ministerio_de_Economia_y_Competitividad
Ministerio_de_Economia_y_Competitividad

 

New initiative in Parkinson’s Disease, addressing unmet research needs to understand mental comorbidities

Scientists from across the EU have come together to form a consortium aiming to investigate anxiety as a comorbidity of Parkinson’s Disease (PD). Comorbid anxiety is not simply a response to the distress of the motor disabilities caused by PD but is in fact a direct result of neural changes caused by PD. Furthermore, people with PD who experience anxiety also tend to have much worse symptoms and motor difficulties compared to those who do not experience anxiety. As such, managing PD anxiety may also alleviate other PD morbidities. Better understanding of the neural changes which occur in the brain during PD could be clinically targeted to improve prevention, diagnosis, and management of comorbidities. Despite this potential, limited research has yet explored comorbid anxiety in PD, thus the AND-PD project began work in 2020 to address this unmet need.

Spearheaded by Prof Rosario Moratalla at the Spanish National Research Council (CSIC), AND-PD brings together world-leading experts from across research and clinical disciplines. The project has already begun to define and identify the mechanisms that lead to comorbid anxiety in PD, and recently held a virtual meeting to discuss the progress so far. To quote Prof Moratalla during this meeting: “The goals of AND-PD not only have the potential to revolutionise scientific understanding of the relationship between physical and mental disabilities, but will also have a great positive impact on the well-being of those living with PD as we understand better how to assist them”.

The project is working to unravel how brainstem neural circuitry is disrupted during PD, by developing and refining research models. As AND-PD models these changes, methods to prevent and even reverse these neurological disruptions will also be developed. Finally, thanks to the close cooperation between researchers and clinicians in the consortium, these findings will begin to be translated into the clinic, to bring the benefits to people living with PD sooner.

AND-PD will take PD research in new directions, bringing knowledge that will contribute to our understanding of other neurological disorders beyond PD.

As well as the Spanish National Research Council (CSIC), the AND-PD partners are: Fondazione Istituto Italiano di Tecnologia, Karolinska Institutet, Universite de Bordeaux, The Hebrew University of Jerusalem, Modus Research and Innovation Ltd, Transine Therapeutics ltd, University College London, King’s College London, Motac France and Fundacion Para La Investigacion Medica Aplicada.

Further details are available on the AND-PD website (https://www.and-pd.com/), or can be requested through email at Esta dirección de correo electrónico está siendo protegida contra los robots de spam. Necesita tener JavaScript habilitado para poder verlo.. For regular updates, you can follow the AND-PD project on Twitter (@ANDPDProject1) and on LinkedIn (www.linkedin.com/in/and-pd-project).

 

 

María Llorens-Martín ha sido galardonada con la Beca ERC HumAN

En el proyecto Interrogando la Neurogénesis del Hipocampo Humano Adulto, su grupo pretende desvelar los mecanismos que controlan esta extraordinaria forma de plasticidad que se produce en el cerebro humano.

 

 

Durante dos días, el XIV Foro CIBERNED ha reunido vía online a diferentes expertos e investigadores en el campo de la investigación en enfermedades neurodegenerativas

La incidencia de la COVID-19 también ha sido protagonista importante del encuentro

Neuronas inmaduras en el giro dentado de un ratón sobrexpresando los factores de Yamanaka. – Alberto García Rodríguez - CBMSO

Neuronas inmaduras en el giro dentado de un ratón sobrexpresando los factores de Yamanaka. – Alberto García Rodríguez - CBMSO

Ha aplicado una técnica de reversión celular en cobayas ratones de 10 meses y ha observado que regiones del hipocampo regresan a los niveles de un ejemplar de 6 meses

Podría ser una estrategia eficaz en el futuro para atenuar el envejecimiento del cerebro y retrasar el avance de enfermedades neurodegenerativas

Durante siglos, sociedades indígenas de la Amazonia han utilizado la ayahuasca, un té alucinógeno, con fines chamánicos. Un grupo de investigación liderado por la Universidad Complutense de Madrid ha demostrado, en modelos animales, que esta bebida es capaz de formar neuronas y otras células cerebrales, convirtiéndose así en una potencial terapia para trastornos psiquiátricos y enfermedades neurodegenerativas. 

Solicitamos su permiso para obtener datos estadísticos de su navegación en esta web, en cumplimiento del Real Decreto-ley 13/2012. Si continúa navegando consideramos que acepta el uso de cookies. OK | Más información